The Food and Drug Administration this week issued guidance intended to clarify the agency’s expectations when electronic health records are used as a source of data in clinical investigations. The guidance applies to clinical investigations of human drugs and biological products, medical devices and combination products, including investigations conducted in clinical practice settings.

Related News Articles

Headline
Commenting Friday on the Office of the National Coordinator’s draft strategy to reduce regulatory and administrative burden related to health information…
Headline
The Government Accountability Office today released a congressionally-mandated report examining approaches and challenges to matching patients to their…
Blog
In this AHA Stat blog post, Elisa Arespacochaga, vice president of AHA's Physician Alliance, highlights how three organizations – HCA Healthcare, Erlanger…
Headline
The Department of Health and Human Services' Office of the National Coordinator for Health IT today released for comment a draft strategy on reducing…
Headline
Critical access hospitals that did not achieve meaningful use in the Medicare Electronic Health Record Incentive Program for the 2017 reporting period can…
Headline
Given the high adoption rate of certified electronic health records, the EHR Reporting Program should “emphasize reporting criteria that indicate h